Research programme: amyloid precursor protein secretase inhibitors - Elan
Alternative Names: ELND007Latest Information Update: 04 Nov 2017
At a glance
- Originator Elan Pharmaceuticals
- Class Pyrazoles; Small molecules; Sulfonamides
- Mechanism of Action Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 03 Aug 2011 Early investigations for β-secretase inhibitors are ongoing; preclinical development for ELND 007 has been discontinued
- 13 Apr 2007 Preclinical development is ongoing